Articles from Kurin, Inc.

Kurin, Inc., a leader in innovative blood culture collection technology designed to reduce contamination and improve patient outcomes, announced today that the United States Court of Appeals for the Federal Circuit has ruled in Kurin’s favor in a patent dispute brought by Magnolia Medical Technologies accusing Kurin’s Lock of infringement. The U. S. District Court had previously ruled in Kurin’s favor and the appellate court affirmed the district court’s judgment of non-infringement.

Kurin, Inc., a certified Minority Business Enterprise, and The Ohio State University Wexner Medical Center are working together to reduce contaminated blood cultures and improve high quality healthcare at Ohio State patient care centers.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that Chief Judge Connolly of the U.S. District Court for the District of Delaware entered Final Judgment that Kurin does not infringe Magnolia Medical, Inc.’s patent. The district court proceedings in the patent infringement lawsuit brought by Magnolia in 2019 are now closed.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced Christine Arme as their Chief Commercial Officer. Christine has been in the health care industry for 35 years, working in both start-up and scaled growth stage healthcare organizations in both a domestic and international capacity. Most recently, Christine served as the Vice President of Healthcare Systems at Solventum (formerly 3M Healthcare), where she has been since 2015. She led the Key Account organization for the Medical Surgical business unit, which is the largest business group within Solventum.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that Chief Judge Connolly of the U.S. District Court in Delaware issued an opinion in the patent litigation brought by Magnolia Medical, Inc. finding that “Kurin is entitled to a judgment of noninfringement of claims 1 and 24 of the #483 patent as a matter of law.”

Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced record revenues for the first quarter of 2024, following a record 2023. Despite a challenging healthcare environment, revenue in Q1 was ~30% higher than Q1 2023 and ~8% higher than Q4 2023, which was also a record quarter for Kurin.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has issued a Reexamination Advisory Action regarding the relevant claims of the ‘483 patent that Magnolia Medical asserted against the Kurin Lock product. The Patent Office found that Magnolia’s arguments regarding claims 1 and 24 do not overcome its prior final rejection of these claims, and noted that any finally rejected claims will be cancelled.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today that the US Patent and Trademark Office has issued a Final Rejection in its reexamination of claims 1 and 24 of U.S. Patent No. 10,039,483 (the ‘483 patent). Claims 1 and 24 of the ‘483 patent were asserted by Magnolia Medical against Kurin’s Lock product in a patent infringement case in Delaware Federal Court. The USPTO Examiner has rejected Magnolia’s arguments regarding patentability, and the pertinent claims of that patent now stand as rejected.

Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced record revenues for the third quarter of 2023. In spite of 2023’s economic challenges for hospitals and other adverse market conditions, revenue growth in Q3 was significantly higher than Q2 of this year and when compared to the same period last year.

Kurin, Inc. has been named the 2023 Diverse Supplier of the Year by Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company. The recognition was celebrated Sept. 18-21 at the 2023 Vizient Connections Summit in Las Vegas.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has rejected the relevant claims of the ‘483 patent that Magnolia Medical asserted against Kurin. The Patent Office determined that multiple examples of prior art render claims 1 and 24 unpatentable.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, provided an update on the ongoing patent infringement case brought against Kurin by Magnolia Medical. It has been more than a year since the jury trial concluded and the Court has stayed Kurin’s motion for indefiniteness, pending an upcoming motion for judgment of noninfringement. In a lengthy accompanying opinion, the Court stated that “it seems likely that Kurin will prevail on its renewed motion for [judgment] of noninfringement of at least claim 1 and perhaps claim 24 as well.”

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today the full-scale launch of Kurin Jet, which has joined the Kurin Lock family. The original member of the Kurin Lock family, now named the Kurin Flash, is the market-leading product in this space. The Kurin Jet provides a significant technological advancement over Kurin Flash.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today that the US Patent and Trademark Office has granted Kurin’s Ex Parte request to reexamine the validity of U.S. Patent No. 10,039,483 (the ‘483 patent) that is asserted by Magnolia Medical in ongoing patent litigation. The Examiner noted there were multiple “Substantial New Questions of Patentability” that merit review.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today that the Food and Drug Administration has issued a 510(k) clearance for the Kurin product line. Kurin now has four 510(k) clearances from the FDA. The recent clearance says, in part, that Kurin reduces the frequency of blood culture contaminations*.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, commends the Centers for Disease Control and Prevention (CDC) for their just-released publication on blood culture contamination. The paper stresses the importance of reducing these preventable contaminations and highlights how devices, like Kurin, have been shown to be effective in this regard. The CDC specifically states: “There are devices that are commercially available that have shown promise in further reducing blood culture contamination rates. These devices initially divert a small amount of potentially contaminated blood and then collect blood for the blood culture.”

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today the limited commercial release of Kurin Jet™, a significant technological advance over Kurin’s own market-leading Kurin Lock®. The new ventless device is not at issue in the lawsuit with Magnolia Medical.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced record revenues for 2022. Revenue growth in 2022 was dramatic, increasing over 60% over 2021 revenue.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced the results of their recent FDA inspection.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, provides an update to the most recent moves by Magnolia Medical Technologies. This week, Magnolia filed a motion in the US District Court of Delaware for a permanent injunction, hoping to take Kurin off the market.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that their previously mentioned Advance Safety Needle System™ has entered full scale production on their automated machine. The Advance needle was tested in 2021, has been used in Kurin accounts since last year and is now widely available.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that they have commenced the commercial launch of their push-button needle, to be used as part of Kurin blood culture sets. The Advance Safety Needle System was tested in 2021 and is now being sold into accounts using Kurin.

Kurin, Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture sets, announced the signing of a recent agreement with AllSpire Health GPO. The agreement is sole source and is for three years.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced record revenues in December and the 4th quarter. 2021 revenue growth over 2020 was dramatic.

Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced that 3rd quarter revenues continued their record growth with the largest quarterly revenue in the company’s history. Kurin also reports that Q3 revenue grew 121% over revenue in the third quarter of 2019, before the pandemic began and a 43% increase over revenue in the third quarter of 2020, during the pandemic.

Kurin, Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today a new clinical study supporting the efficacy of their blood culture collection product. Authors from Guy’s and St. Thomas’ NHS Foundation Trust, a prestigious London-based hospital, presented their data at the recent Infection Prevention Society conference in Liverpool. They reported that blood culture contaminations were reduced 66% after implementing Kurin, and the authors noted both financial savings for their hospital, as well as a positive impact for their patients.

Kurin Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that July revenues represent their highest monthly total in their history. Kurin also reports that July exceeded 200% over the same month in 2019, before the pandemic began.